NCT07084831 - A Prospective, Open-label, Single-arm, Multicenter Study Evaluating the Efficacy of One Year Treatment With Xanomeline/Trospium on Cognitive Impairment in Clinically Stable Adult Participants With Schizophrenia. | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2028

Study Completion Date

July 1, 2028

Conditions

Schizophrenia; PsychosisCognitive Impairment

Interventions

DRUG

Xanomeline/trospium

Participants will receive xanomeline/trospium during the trial

Trial Locations (2)

Sheba Medical Center, Ramat Gan

University Medical Center Groningen, Groningen